# Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)

> **NCT04093505** · PHASE3 · TERMINATED · sponsor: **University Hospital Heidelberg** · enrollment: 28 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Gemtuzumab Ozogamicin 147
- **DRUG:** Gemtuzumab Ozogamicin 1
- **DRUG:** Glasdegib
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT04093505
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-01
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-06-23
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Study turned out no longer feasible. End of Recruitment: 25.5.2022
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04093505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04093505, "Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04093505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*